Prescient Therapeutics : March 2019 Appendix 4C - Quarterly

ASX Announcement

March 2019 Quarterly Update & Appendix 4C

Melbourne, Australia (24 April 2019): Clinical-stage targeted oncology company Prescient

Therapeutics Limited (ASX: PTX) today reported its March 2019 quarter results and operating highlights.

Financial update

The business ended the quarter with cash reserves of A$4.68 million. This included an Australian Government Research and Development tax refund of A$939,423 in January 2019 and receipt of Tranche 1 Placement funds of A$1.77 million before costs.

During the quarter, Prescient announced it had raised A$9.1 million through a Placement and Non-Renounceable Rights Issue. The Rights Issue and second tranche of the Placement will close in April. The capital raising was supported by existing and new institutional life science investors based in the US and Australia. The business is now well funded to execute on its important near term clinical and strategic milestones.

Costs for the quarter included the ongoing clinical trials for PTX-200, preparations for the imminent start of human trials for PTX-100 and investment in manufacturing to ensure supply for our expanded clinical programs.

Clinical progress

Prescient has multiple clinical programs in partnership with some of the world's leading cancer clinicians. The Company is looking forward to initiating the Phase 1 study of PTX-100 in a unique basket trial in a range of cancers and opening our first trial site in Australia.

Business Development

Prescient is working on a number of initiatives to enhance shareholder value and further expand our product pipeline. Management and the Board continue to actively evaluate potential external opportunities that are complementary and strategically valuable.

For more information please contact:

Steven Yatomi-Clarke	Andrew Geddes
CEO & Managing Director	CityPR
Prescient Therapeutics Limited	[phone]
[phone]

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Prescient's lead drug candidate PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This promising compound is now the focus of three current clinical trials:

•Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and Florida's H. Lee Moffitt Cancer Center (Moffitt). PTX-200 showed encouraging efficacy signals in the Phase 1b study, with twice the expected response rate.

•Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted the Moffitt; Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.

•Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1(GGT-1). It inhibits the activation of Rho, Rac and Ral circuits in cancer cells, which act as key oncogenic pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors and will be the focus of studies in Ras and RhoA mutant malignancies

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward- looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-

looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

2+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity
Prescient Therapeutics Limited
ABN	Quarter ended ("current quarter")
56 006 569 106	31 March 2019

Consolidated statement of cash flows

Current quarter	Year to date
$A'000	(9 months)
	$A'000

1.	Cash flows from operating activities
1.1	Receipts from customers		-	-
1.2	Payments for
	(a)	research and development	(882)	(2,049)
	(b)	product manufacturing and operating	-	-
		costs
	(c)	advertising and marketing	-	-
	(d)	leased assets	-	-
	(e)	staff costs	(182)	(679)
	(f)	administration and corporate costs	(153)	(765)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		14	68
1.5	Interest and other costs of finance paid		-	-
1.6	Income taxes paid		-	-
1.7	Government grants and tax incentives (R&D)		939	939
1.8	Other (provide details if material)		-	18
1.9	Net cash from / (used in) operating		(264)	(2,468)
	activities

2.	Cash flows from investing activities
2.1	Payments to acquire:
	(a) property, plant and equipment		-	-
	(b)	businesses (see item 10)	-	-
	(c)	investments	-	-

+ See chapter 19 for defined terms
1 September 2016	Page 1

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows

Current quarter	Year to date
$A'000	(9 months)
	$A'000

	(d)	intellectual property	-	-
	(e)	other non-current assets	-	-
2.2	Proceeds from disposal of:
	(a) property, plant and equipment		-	-
	(b)	businesses (see item 10)	-	-
	(c)	investments	-	-
	(d)	intellectual property	-	-
	(e)	other non-current assets	-	-
2.3	Cash flows from loans to other entities		-	-
2.4	Dividends received (see note 3)		-	-
2.5	Other (cash on deposit with a term greater		-	-
	than 3 months)
2.6	Net cash from / (used in) investing		-	-
	activities

3.	Cash flows from financing activities
3.1	Proceeds from issues of shares	1,766	1,766
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of	(137)	(137)
	shares, convertible notes or options
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and	-	-
	borrowings
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing	1,629	1,629
	activities

4.Net increase / (decrease) in cash and cash equivalents for the period

4.1Cash and cash equivalents at beginning of

	quarter/year to date	3,299	5,485
4.2	Net cash from / (used in) operating	(264)	(2,468)
	activities (item 1.9 above)
4.3	Net cash from / (used in) investing activities	-	-
	(item 2.6 above)
4.4	Net cash from / (used in) financing activities	1,629	1,629
	(item 3.10 above)
+ See chapter 19 for defined terms
1 September 2016			Page 2